CN104884050A - 用于治疗hiv感染的药物组合物 - Google Patents

用于治疗hiv感染的药物组合物 Download PDF

Info

Publication number
CN104884050A
CN104884050A CN201380068729.6A CN201380068729A CN104884050A CN 104884050 A CN104884050 A CN 104884050A CN 201380068729 A CN201380068729 A CN 201380068729A CN 104884050 A CN104884050 A CN 104884050A
Authority
CN
China
Prior art keywords
pharmaceutical composition
water
cellulose
salt
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380068729.6A
Other languages
English (en)
Chinese (zh)
Inventor
维克拉姆·辛柯·普尼娅
詹纳蒂·安德垒维奇·巴秋宁
纳塔利娅·尤里耶夫娜·马雷赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fa Maxitai Joint-Stock Co
Original Assignee
Fa Maxitai Joint-Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49957619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104884050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fa Maxitai Joint-Stock Co filed Critical Fa Maxitai Joint-Stock Co
Publication of CN104884050A publication Critical patent/CN104884050A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201380068729.6A 2012-12-29 2013-09-19 用于治疗hiv感染的药物组合物 Pending CN104884050A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012158141 2012-12-29
RU2012158141/15A RU2505286C1 (ru) 2012-12-29 2012-12-29 Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
PCT/RU2013/000817 WO2014104929A1 (fr) 2012-12-29 2013-09-19 Composition pharmaceutique pour traiter une infection par le vih

Publications (1)

Publication Number Publication Date
CN104884050A true CN104884050A (zh) 2015-09-02

Family

ID=49957619

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380068729.6A Pending CN104884050A (zh) 2012-12-29 2013-09-19 用于治疗hiv感染的药物组合物

Country Status (18)

Country Link
US (1) US10493034B2 (fr)
EP (1) EP2939665B1 (fr)
CN (1) CN104884050A (fr)
CA (1) CA2896710C (fr)
CY (1) CY1121660T1 (fr)
DK (1) DK2939665T3 (fr)
EA (1) EA029586B1 (fr)
ES (1) ES2729568T3 (fr)
HR (1) HRP20190882T1 (fr)
HU (1) HUE043694T2 (fr)
LT (1) LT2939665T (fr)
PL (1) PL2939665T3 (fr)
PT (1) PT2939665T (fr)
RS (1) RS58837B1 (fr)
RU (1) RU2505286C1 (fr)
SI (1) SI2939665T1 (fr)
TR (1) TR201908007T4 (fr)
WO (1) WO2014104929A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105194687A (zh) * 2015-10-22 2015-12-30 浙江医药高等专科学校 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017086835A1 (fr) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Composition pharmaceutique possédant un effet thérapeutique vis-à-vis des maladies démyélinisantes (et variantes)
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (fr) 2021-04-07 2022-10-13 Batelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
WO2024085784A1 (fr) * 2022-10-19 2024-04-25 Общество С Ограниченной Ответственностью "Промомед Рус" Composition pharmaceutique et agent médicamenteux pour traiter une infection par coronavirus
WO2024091148A2 (fr) * 2022-10-26 2024-05-02 Общество С Ограниченной Ответственностью "Абицея Медикал Технолоджис" Concentré balnéologique liquide, et ampoule avec échelle de mesure et dispositif de dosage pratique du concentré balnéologique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CN101925350A (zh) * 2007-12-24 2010-12-22 希普拉有限公司 抗逆转录病毒的组合
CN101951891A (zh) * 2008-01-11 2011-01-19 希普拉有限公司 固态药物剂型
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
WO2010006050A1 (fr) * 2008-07-09 2010-01-14 Purdue Research Foundation Inhibiteurs de la protéase du vih et procédés d'utilisation
EP2714683A4 (fr) * 2011-05-27 2014-11-05 Hetero Research Foundation Ritonavir amorphe co-précipité
US20150004237A1 (en) * 2012-01-09 2015-01-01 Virginia Tech Intellectual Properties, Inc. Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs
US20150045400A1 (en) * 2012-03-01 2015-02-12 Bandi Parthasaradhi Reddy Ritonavir compositions
WO2014184553A1 (fr) * 2013-05-15 2014-11-20 Cipla Limited Compositions pharmaceutiques antirétrovirales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CN101925350A (zh) * 2007-12-24 2010-12-22 希普拉有限公司 抗逆转录病毒的组合
CN101951891A (zh) * 2008-01-11 2011-01-19 希普拉有限公司 固态药物剂型
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105194687A (zh) * 2015-10-22 2015-12-30 浙江医药高等专科学校 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法

Also Published As

Publication number Publication date
EP2939665B1 (fr) 2019-03-20
TR201908007T4 (tr) 2019-06-21
HRP20190882T1 (hr) 2019-09-20
US20150297526A1 (en) 2015-10-22
US10493034B2 (en) 2019-12-03
ES2729568T3 (es) 2019-11-04
CA2896710A1 (fr) 2014-07-03
WO2014104929A1 (fr) 2014-07-03
SI2939665T1 (sl) 2019-08-30
CY1121660T1 (el) 2020-07-31
RU2505286C1 (ru) 2014-01-27
PL2939665T3 (pl) 2020-01-31
LT2939665T (lt) 2019-07-25
EA029586B1 (ru) 2018-04-30
EP2939665A1 (fr) 2015-11-04
HUE043694T2 (hu) 2019-09-30
EP2939665A4 (fr) 2016-06-01
EA201500710A1 (ru) 2015-10-30
RS58837B1 (sr) 2019-07-31
PT2939665T (pt) 2019-06-14
DK2939665T3 (da) 2019-06-11
CA2896710C (fr) 2019-03-26

Similar Documents

Publication Publication Date Title
US20230122911A1 (en) Formulations of enzalutamide
CN104884050A (zh) 用于治疗hiv感染的药物组合物
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
Rahman et al. Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
CN102470121B (zh) 包含决奈达隆的药物组合物
KR20190062260A (ko) 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법
JP7058104B2 (ja) アプレピタントを有効成分とする医薬錠剤
KR101910707B1 (ko) 복용순응도가 향상된 메트포르민 서방성 정제 및 이의 제조방법
EP3305282A2 (fr) Composition de préparation solide contenant du pranlukast à biodisponibilité améliorée et procédé pour sa préparation
RU2543322C1 (ru) Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
Thakur et al. Novel application of mixed solvency concept to develop and formulate dry powder injection for reconstitution of a poorly water soluble drug, amlodipine besylate and their evaluations
WO2023108942A1 (fr) Composition pharmaceutique de nucléoside deutéré oral ou d'un sel pharmaceutiquement acceptable correspondant, son procédé de préparation et son application
KR100908193B1 (ko) 애엽추출물의 가용화 방법
KR100591786B1 (ko) 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
CN104000788A (zh) 一种含恩曲他滨的片剂及其制备方法
EA040125B1 (ru) Фармацевтическая композиция, обладающая активностью против вич-инфекции, включающая лопинавир и ритонавир на сорбенте

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902

RJ01 Rejection of invention patent application after publication